1. What Is the Liquid Biopsy Market?
The Liquid Biopsy Market covers the blood-based tests that detect circulating tumour DNA, circulating tumour cells, or exosomes from cancer to provide information about tumour presence, mutations, or treatment response without invasive tissue sampling, supplied to oncology and cancer screening programmes. Oncologists use liquid biopsies to detect targetable mutations in patients where tissue biopsy is difficult, monitor treatment response through serial blood draws, and identify resistance mutations that emerge under therapy. The market serves advanced cancer management primarily, with early cancer detection as an emerging and potentially transformational second application. It includes circulating tumour DNA plasma genotyping assays, circulating tumour cell tests, and multi-cancer early detection tests, with demand driven by targeted therapy selection, treatment monitoring, and the ambition to screen for cancer before symptoms arise.
2. Liquid Biopsy Market Size & Forecast
3. Emerging Technologies
- Comprehensive plasma ctDNA genotyping identifying targetable mutations for therapy selection in advanced solid tumours.
- Multi-cancer early detection using cell-free DNA methylation signatures to identify cancer signals across tissue types.
- Minimal residual disease ctDNA testing after curative treatment detecting residual tumour for relapse prediction.
- Treatment response monitoring using serial ctDNA quantification to assess tumour burden changes.
Such innovations are driving change across adjacent industries too. Discover more in our Point Of Care Diagnostics Market.
4. Key Market Opportunity
The largest near-term opportunity in the Liquid Biopsy market lies in oncologists using liquid biopsy for mutation profiling where tissue is insufficient or unavailable for repeat genotyping. A second, faster-growing opportunity lies in health systems piloting multi-cancer early detection in cancer screening programmes for high-risk populations. As adoption broadens, the addressable opportunity is expanding from early deployments toward wider commercial use, with Europe positioned for the most rapid growth through 2034.
5. Top Companies in the Liquid Biopsy Market
The following organisations hold leading positions in the Liquid Biopsy Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Guardant Health
- Foundation Medicine (Roche)
- Grail (Illumina)
- Exact Sciences
- Personal Genome Diagnostics
- Biodesix
- Angle
- Inivata (NovaBay)
- Menarini Silicon Biosystems
- Oncobiologics
6. Market Segmentation
The Liquid Biopsy Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Technology | ctDNA NGS PCR-Based Circulating Tumour Cell Exosome |
| By Application | Therapy Selection Treatment Monitoring Minimal Residual Disease Multi-Cancer Screening |
| By Cancer Type | Lung Colorectal Breast Prostate Multi-Cancer |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Liquid Biopsy Market trajectory over the forecast period:
Plasma Circulating Tumour DNA Genotyping Has Established Clinical Utility for Therapy Selection in Lung.Plasma circulating tumour DNA genotyping has established clinical utility for therapy selection in lung cancer, colorectal cancer, and other solid tumours where tissue biopsy is difficult, requires time, or has already been exhausted. Guardant Health's Guardant360 and Foundation Medicine's FoundationOne Liquid CDx are FDA-approved comprehensive plasma genotyping assays that identify EGFR, KRAS, ALK, and other targetable mutations from plasma. The approval of plasma-based assays as companion diagnostics for specific targeted therapies has embedded liquid biopsy in oncology treatment algorithms. This clinical adoption in late-stage cancer is the established market.
Multi-Cancer Early Detection Is.Multi-cancer early detection is the aspirational high-growth application, as tests like GRAIL's Galleri use cell-free DNA methylation analysis to detect signals from more than 50 cancer types from a single blood draw before symptoms appear. The clinical evidence for early detection accuracy in multiple cancer types is accumulating in prospective trials. If multi-cancer early detection tests demonstrate survival benefit and gain reimbursement, the addressable population would be the entire screening-eligible adult population. This potential market is transformational but depends on prospective evidence and payer coverage decisions that remain outstanding.
Minimal Residual Disease Detection Represents a Distinct Clinical Application.Minimal residual disease detection represents a distinct clinical application, as ultra-sensitive ctDNA testing after surgery or treatment identifies residual tumour cells that predict relapse before imaging confirms recurrence. This surveillance application provides actionable clinical information that alters management.
For related market intelligence, see the In Vitro Diagnostics Market.
8. Segmental Analysis
By application, the therapy selection segment dominated the Liquid Biopsy Market in 2025, as companion diagnostic plasma genotyping for targeted therapy selection represents the largest established commercial application.
By application, the multi-cancer screening segment is projected to register the highest CAGR in the Liquid Biopsy Market through 2034, as early detection test adoption grows pending clinical evidence and reimbursement, driving the fastest-growing application category within the market.
9. Regional Analysis
Regional demand patterns across the Liquid Biopsy Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Liquid Biopsy Market in 2025, accounting for the largest share of revenue. Moreover, the United States leads through FDA approval of plasma genotyping companion diagnostics, the highest adoption of Guardant360 and FoundationOne Liquid CDx in oncology, and the presence of Guardant Health and GRAIL as the leading liquid biopsy developers. In addition, premium test pricing and broad oncology adoption anchor revenue leadership.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Liquid Biopsy Market through 2034. The primary driver is European healthcare system adoption of liquid biopsy for advanced cancer management and pilot programmes for multi-cancer early detection in national cancer plans. Moreover, france's National Cancer Plan and UK NHS programmes have expressed interest in liquid biopsy for cancer screening. The combination of these demand drivers and an expanding base positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Liquid Biopsy Market was valued at USD 4.25 Bn in 2025 and is projected to reach USD 40.86 Bn by 2034, growing at a CAGR of 28.6% over the 2026–2034 forecast period.
The Liquid Biopsy Market is projected to grow at a CAGR of 28.6% from 2026 to 2034.
North America dominated the Liquid Biopsy Market in 2025, accounting for the largest share of revenue.
The leading companies in the Liquid Biopsy Market include Guardant Health, Foundation Medicine (Roche), Grail (Illumina), Exact Sciences, Personal Genome Diagnostics, Biodesix, Angle, Inivata (NovaBay), Menarini Silicon Biosystems, Oncobiologics.
Plasma circulating tumour dna genotyping has established clinical utility for therapy selection in lung.
By application, the therapy selection segment dominated the Liquid Biopsy Market in 2025, as companion diagnostic plasma genotyping for targeted therapy selection represents the largest established commercial application.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.